Published 3 hours ago • loading... • Updated 1 hour ago

Novartis Shares Down as Failed Cholesterol Drug Study Increases Pipeline Pressure

Summary by WTVB

LONDON, Sept 7 (Reuters) - Shares of Novartis fell 3.3% on Monday morning after its cholesterol drug failed ‌in a closely watched study, casting fresh doubt on the therapeutic approach and raising the ‌stakes for the ⁠Swiss drugmaker's upcoming ⁠data...

7 Articles

WTVB

Center

Novartis shares down as failed cholesterol drug study increases pipeline pressure

2 hours ago

Read Full Article

Reformatorisch Dagblad

Reposted by

welingelichtekringen.nl

Right

Investors Taken Aback by Setback at Swiss Pharmaceutical Company Novartis

Novartis lost more than 3 percent of its market value on the Zurich stock exchange on Monday. The Swiss pharmaceutical company suffered a second setback in its drug research within a week, after a promising heart medication turned out not to work as well as expected in an advanced study. Investors were shocked by this.

2 hours ago·Apeldoorn, Netherlands (Kingdom of the)

Read Full Article

Moneycontrol

Lean Right

Novartis heart-drug failure deepens setbacks, hits rivals

Novartis is counting on a string of new medicines to sustain growth when some of its biggest products lose patent protection.

2 hours ago·Mumbai, India

Read Full Article

european-biotechnology.com

Novartis’ Lp(a) drug misses Phase 3 endpoint - European Biotechnology Magazine

Novartis’ pelacarsen failed to reduce cardiovascular events in the first Phase 3 outcomes trial of an Lp(a)-lowering drug, despite successfully lowering the genetically driven cardiovascular risk factor.

1 hour ago

Read Full Article

Nieuws.nl

Investors Are Shocked: Novartis Fails After Research Flaw

AMSTERDAM (ANP/BLOOMBERG) - Novartis lost more than 3 percent in market value on the Zurich stock exchange on Monday. The Swiss pharmaceutical company suffered a second setback in its drug research within a week, after a promising heart drug was discovered in an advanced study.

2 hours ago

Read Full Article